Increased expression of RUNX3 inhibits normal human myeloid development

Area of Science:

• Molecular Biology
• Hematopoiesis
• Cancer Biology

Background:

• RUNX3 is a transcription factor implicated in acute myeloid leukemia (AML).
• Its precise role in normal myeloid development and AML pathogenesis remains unclear.

Purpose of the Study:

• To investigate RUNX3 expression patterns during normal hematopoiesis and in AML.
• To determine the functional impact of RUNX3 dysregulation on myeloid differentiation and development.

Main Methods:

• Analysis of RUNX3 mRNA expression in hematopoietic stem and progenitor cells (HSPC) and AML patient samples.
• Functional studies involving RUNX3 overexpression and knockdown in human HSPC.
• RNA-sequencing to identify downstream target genes affected by RUNX3.

Main Results:

• RUNX3 mRNA expression decreased during normal granulocytic differentiation but was often elevated in AML subtypes.
• RUNX3 overexpression in HSPC inhibited myeloid differentiation, proliferation, and colony formation, particularly affecting the granulocytic lineage.
• RUNX3 knockdown did not impair normal myeloid development; RNA-seq revealed downregulation of key myeloid genes (e.g., KIT, RUNX1) and upregulation of lymphoid genes (e.g., KLRB1, TBX21).

Conclusions:

• Elevated RUNX3 expression in AML may contribute to developmental arrest by promoting a lymphoid transcriptional program.
• RUNX3 acts as an inhibitor of granulocytic differentiation, potentially explaining its role in AML pathogenesis.